Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
GD

GDTCStockCytoMed Therapeutics Limited

Nasdaq Capital Market · Healthcare · SG

$0.84 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment GDTC's does — no target price to set, unlike a price alert.

Stable Ratio screen, 6 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine · assessed 2026-08-28
6 of 7 pass our own screen — the standards disagree
Purification 100.00% *HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
47
of 100
Setup confidence — system conviction, not win probabilityD

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 4 timeframes bullish · 70.6% aligned
VWAPPrice holding above VWAP ($0.78)
VolumeRelative volume 3.1× the 20-day average
Momentum10-day rate of change -4.5%
Overall readNEUTRAL — No Edge

CytoMed Therapeutics Limited (GDTC) is currently considered halal (Sharia-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$4.16
+395.2% · 1 analysts
Institutional own.
1.2%
of shares
Momentum (10d)
-4.5%
rate of change
SMC grade
D · 47
70.6% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2025-12-31)
D · 47
SMC grade — 70.6% timeframe alignment
-4.5%
Rate of change (10d)
$4.16
Price target (+395.2%) · 1 analysts
1.2%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to GDTC’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $9.1M as of 2026-10-08.

Business activity: not screened

We have not screened this company's line of business, so these ratios say nothing about whether what it does is permissible.

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 3.52% 30.00% Pass(26.5pp buffer)
Interest-bearing investments 17.99% 30.00% Pass(12.0pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 5.13% 33.00% Pass(27.9pp buffer)
Interest-bearing investments 26.24% 33.00% Pass(6.8pp buffer)
Non-liquid assets 54.13% at least 20.00% Pass(34.1pp above the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 5.13% 33.33% Pass(28.2pp buffer)
Cash + interest-bearing securities 26.24% 33.33% Pass(7.1pp buffer)
Accounts receivable 45.87% 33.33% Fail(12.5pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 5.13% 33.33% Pass(28.2pp buffer)
Cash + interest-bearing securities 26.24% 33.33% Pass(7.1pp buffer)
Accounts receivable 45.87% 50.00% Pass(4.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.81% 33.00% Pass(31.2pp buffer)
Cash + interest-bearing securities 9.26% 33.00% Pass(23.7pp buffer)
Accounts receivable 6.93% 33.00% Pass(26.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.58% 33.00% Pass(31.4pp buffer)
Cash + interest-bearing securities 8.11% 49.00% Pass(40.9pp buffer)
Accounts receivable 6.06% 49.00% Pass(42.9pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.58% 33.33% Pass(31.7pp buffer)
Cash + interest-bearing securities 8.11% 33.33% Pass(25.2pp buffer)
Accounts receivable 14.17% 49.00% Pass(34.8pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

FTSE Shariah Global Equity Index Series (% of total assets)receivables ratio 4.1pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
MSCI Islamic Index (% of total assets)receivables ratio 12.5pts

The numbers the ratios are built from

Read from GDTC's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $252.3K 2025-12-31 Revenue
Interest-bearing debtShort and long-term borrowings $318.5K 2025-12-31 Borrowings
Cash and interest-bearing securitiesCash, equivalents and marketable securities $1.6M 2025-12-31 CashAndCashEquivalents
Total assetsBalance sheet total $6.2M 2025-12-31 Assets
Market capDenominator for AAOIFI $9.1M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $23.7M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $20.5M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2025-12-31 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-10-08.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$6.2M
    Assets · balance sheet as of 2025-12-31
  • Interest-bearing debt$318.5K
    Borrowings · balance sheet as of 2025-12-31
  • Cash and interest-bearing securities$1.6M
    CashAndCashEquivalents · balance sheet as of 2025-12-31
  • Receivables$1.2M
    TradeAndOtherCurrentReceivables · balance sheet as of 2025-12-31
  • Revenue$252.3K
    Revenue · income statement as of 2025-12-31
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2025-12-31
  • Market cap$9.1M
    Market-data quote at screen time, 2026-10-08 · not a filing figure, so no link

What changed, and when

Verdict history for GDTC. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for GDTC has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 6 pass and 1 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-10-08.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (3.5% against a 30% line) would only fail if the market cap fell by 88%, to $1.1M.

AAOIFI's investments ratio is $1.6M cash and interest-bearing investments over a market cap of $9.1M (as of 2026-10-08), 18.0% against a 30% line.

It would fail if the market cap fell to $5.4M (-40%).

AAOIFI would then fail, and the majority verdict would move from Compliant to no verdict (5 of 7 decided standards passing).

At the screen's market cap, cash and interest-bearing investments would have to rise by $1.1M to reach the line.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

1.911.611.321.020.722025-11-192026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
0.75
S2
0.77
S1
0.80
PIVOT
0.82
R1
0.85
R2
0.87
R3
0.90

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
0.6356 – 1.14
±28.51% from 0.889, made 2026-09-29 · resolves 2026-10-06
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG SELL
2 buy · 0 neutral · 10 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)47.90NEUTRAL
Stochastic %K (14)69.12NEUTRAL
CCI (20)-19.07NEUTRAL
Williams %R (14)-30.88NEUTRAL
MACD (12,26,9)-0.00SELL
ROC (10)-3.42SELL
Momentum (10)-0.03SELL
EMA (10)0.84BUY
SMA (10)0.83BUY
EMA (20)0.85SELL
SMA (20)0.87SELL
EMA (30)0.87SELL
SMA (30)0.87SELL
EMA (50)0.88SELL
SMA (50)0.89SELL
EMA (100)0.92SELL
SMA (100)0.91SELL
EMA (200)1.02SELL
SMA (200)0.97SELL

About CytoMed Therapeutics Limited

Healthcare · Biotechnology

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

w2.cytomed.sg ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 2 bullish / 1 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 44
🕐 1H NEUTRAL 15
⏱ 15-Min BEARISH 60
⏲ 5-Min RANGING 180

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-4.5%
Rate of change (10d)
3.1×
Volume vs its 20-day average
-0.02
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.